GlassScriptPhysician profile
Jillian Hale
NPI 1154828952
$1,810.56
in general payments reported to CMS, 2019-2025
20 companies · $519 in 2025
The $519 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.51 · 2022: $99.06 · 2023: $734 · 2024: $419 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577 · Education: $69.99 · Consulting Fee: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.00 |
| Education | $69.99 |
| Consulting Fee | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $343.00 | 2023-2025 | |
| Astellas Pharma US INC | $228.11 | 2022-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $195.04 | 2023-2025 | Endosee, Paragard T 380a, Summit Doppler |
| Evofem Biosciences, INC. | $185.42 | 2022-2025 | Phexxi, Solosec, Phexx |
| Myriad Women'S Health, INC. | $134.10 | 2023 | Myrisk |
| Abbvie INC. | $116.77 | 2022-2024 | |
| Medtronic, INC. | $111.72 | 2021-2023 | Corevalve Evolut R |
| Pfizer INC. | $58.45 | 2024-2025 | |
| Exeltis, USA INC. | $58.08 | 2025 | Slynd |
| Mayne Pharma Commercial LLC | $57.09 | 2023-2025 | |
| Biogen, INC. | $52.20 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $50.86 | 2023-2024 | Twirla |
| Sumitomo Pharma America, INC. | $49.38 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $45.47 | 2023 | Cologuard Collection Kit |
| Organon LLC | $30.20 | 2023 | Nexplanon |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $28.18 | 2024 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Merck Sharp & Dohme LLC | $19.19 | 2024 | Gardasil 9, Gardasil |
| Millicent US INC | $17.85 | 2024 | Femring |
| Minerva Surgical, INC | $16.22 | 2024 | |
| Aspira Women'S Health INC | $13.23 | 2023 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.